Since NO level is progressively decreased as PAH worsens, the efficacy of PDE5 inhibitors as monotherapy or the NO‐dependent activity of sGC stimulators used as monotherapy may decrease (Klinger & Kadowitz, 2017). Here, PDE5A is linked to pulmonary arterial hypertension.